Quanjun Cui

Dr. Quanjun Cui


Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2020 in Journal of Orthopaedic Translation
Verified
Journal Article
Open access
DZDeWei Zhao
DeWei Zhao
FZFeng Zhang
Feng Zhang
BWBenjie Wang
Benjie Wang
BLBaoyi Liu
Baoyi Liu
LLLu Li
Lu Li
LQLing Qin
Ling Qin
Osteonecrosis of the femoral head (ONFH) is a common and refractory disease in orthopaedic clinics. The number of patients with ONFH is increasing worldwide every year. There are an estimated 8.12 million patients with nontraumatic osteonecrosis in China alone. Treatment of nontraumatic osteonecrosis has always been a clinical challenge for orthopaedic surgeons. To further standardize diagnosis and treatment of ONFH, these guidelines provide not only basic diagnosis, treatment, and evaluation systems for ONFH but also expert advice and standards in many aspects, including epidemiology, aetiology, diagnostic criteria, pathological staging, prevention and treatment options, and postoperative rehabilitation. The aetiological factors of ONFH can currently be divided into two major categories: traumatic and nontraumatic; however, the specific pathological mechanism of ONFH is not completely clear. Currently, the staging system of ONFH formulated by the Association Research Circulation Osseous is widely used in clinical practice. Based on the changes in the intraosseous blood supply at different stages, the corresponding nonsurgical and surgical treatments are recommended, and when there are risk factors for possible ONFH, certain preventive measures to avoid the occurrence of osteonecrosis are recommended. These guidelines provide brief classification criteria and treatment regimen for osteonecrosis. Specification of the aetiology, treatment plan based on comprehensive consideration of the different stages of osteonecrosis, hip function, age, and occupation of the patients are important steps in diagnosis and developing treatment strategies. New advances in the epidemiology, etiology, pathophysiology, imaging, diagnosis and treatment of ONFH have been renewed in this revision. This guideline can be used for reference by orthopedic professionals and researchers, and for standardized diagnosis and treatment management under the clinical guidance, which is conducive to the prevention, treatment and further research of ONFH, improving the diagnosis and treatment level, making patients' symptoms under good control, and improving their quality of life.

1 January 2021 in Journal of Korean Medical Science
Verified
Journal Article
Open access
PDF file
JHJeremy T. Hines
Jeremy T. Hines
WJWoo-Lam Jo
Woo-Lam Jo
QCQuanjun Cui
Quanjun Cui
MMMichael A. Mont
Michael A. Mont
KKKyung-Hoi Koo
Kyung-Hoi Koo
JPJung-Wee Park
Jung-Wee Park
Hines JT, et al. J Korean Med Sci. 2021 May;36(24):e177. https://doi.org/10.3346/jkms.2021.36.e177

1 April 2019 in Orthopedic Clinics of North America
Verified
Journal Article
Closed access
ACAnna Cohen-Rosenblum
Anna Cohen-Rosenblum
QCQuanjun Cui
Quanjun Cui

3 December 2012 in Arthritis
Verified
Journal Article
Open access
PDF file
JSJesse Seamon
Jesse Seamon
TKThomas Keller
Thomas Keller
JSJamal Saleh
Jamal Saleh
QCQuanjun Cui
Quanjun Cui
Nontraumatic osteonecrosis continues to be a challenging problem causing debilitating major joint diseases. The etiology is multifactorial, but steroid- and alcohol-induced osteonecrosis contribute to more than two thirds of all cases with genetic risk factors playing an important role in many other cases, especially when they contribute to hypercoagulable states. While the exact mechanisms remain elusive, many new insights have emerged from research in the last decade that have given us a clearer picture of the pathogenesis of nontraumatic osteonecrosis of the femoral head. Progression to end stage osteonecrosis of the femoral head appears to be related to four main factors: interactions involving the differentiation pathway of osteoprogenitor cells that promote adipogenesis, decreased angiogenesis, direct suppression of osteogenic gene expression and proliferation of bone marrow stem cells, and genetic anomalies or other diseases that promote hypercoagulable states.

4 April 2018 in International Orthopaedics
Verified
Journal Article
Closed access
PDF file
ELEric Larson
Eric Larson
LJLynne C. Jones
Lynne C. Jones
Stuart B GoodmanStuart B Goodman
Stuart B Goodman
KKKyung-Hoi Koo
Kyung-Hoi Koo
QCQuanjun Cui
Quanjun Cui

12 July 2016 in Bone Research
Verified
Journal Article
Open access
AKAdrese M Kandahari
Adrese M Kandahari
XYXinlin Yang
Xinlin Yang
KLKevin A Laroche
Kevin A Laroche
ADAbhijit S Dighe
Abhijit S Dighe
DPDongfeng Pan
Dongfeng Pan
QCQuanjun Cui
Quanjun Cui
In a world where increasing joint arthroplasties are being performed on increasingly younger patients, osteolysis as the leading cause of failure after total joint arthroplasty (TJA) has gained considerable attention. Ultra-high molecular weight polyethylene wear-induced osteolysis is the process by which prosthetic debris mechanically released from the surface of prosthetic joints induces an immune response that favors bone catabolism, resulting in loosening of prostheses with eventual failure or fracture. The immune response initiated is innate in that it is nonspecific and self-propagating, with monocytic cells and osteoclasts being the main effectors. To date, detecting disease early enough to implement effective intervention without unwanted systemic side effects has been a major barrier. These barriers can be overcome using newerin vivoimaging techniques and modules linked with fluorescence and/or chemotherapies. We discuss the pathogenesis of osteolysis, and provide discussion of the challenges with imaging and therapeutics. We describe a positron emission tomography imaging cinnamoyl-Phe-(D)-Leu-Phe-(D)-Leu-Phe-Lys module, specific to macrophages, which holds promise in early detection of disease and localization of treatment. Further research and increased collaboration among therapeutic and three-dimensional imaging researchers are essential in realizing a solution to clinical osteolysis in TJA.